Phase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment

Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新: 2021年11月8日

适应症

试验速览

•1.1. Patients who have undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas
•1.2. Patients with other cancer may be included who have had complete macroscopic resection for unusual malignancies of the pancreas; cancer of the periampullary region; cancer of the intra-pancreatic bile duct; periampullary cancer of uncertain origin
•2. Histological confirmation of the primary diagnosis
•3. Histological examination of all resection margins
•4. No evidence of malignant ascites, liver metastases, spread to other distant abdominal organs, peritoneal metastases, spread to extra-abdominal regions
•5. A World Health Organisation (WHO) performance status =2
•6. Fully recovered from surgery and fit to take part in the trial. Life expectancy of more than 3 months
•7. Able to attend for administration of adjuvant therapy
•8. Able to attend for long-term follow-up
•9. No previous or concurrent malignancy diagnoses
•10. No serious medical or psychological condition precluding adjuvant treatment
•11. Fully informed written consent given

发起方

Cancer Research UK (CRUK) (UK)